News

Technology News

Stealth Bio Details Clinical Development Program

Monday, January 12, 2015 5:14:00 AM PDT | VentureDeal
   Boston, Massachusetts  --  Stealth BioTherapeutics is expanding clinical development for its drug candidates for mitochondria-targeted therapies.

For its lead compounds, Bendavia and Ocuvia, the company has included new trials for heart failure and ophthalmic disorders.

A Phase 2 study in skeletal muscle dysfunction underwent patient recruitment in the US and clinical results are anticipated to begin in the first half of 2015.

The two drug compounds have the potential to modify disease through mitoprotection by preserving energetics and restoring normal energy production in mitochondria.

The company says that the underlying science is "supported by more than 100 independent, peer-reviewed publications and abstracts."

Concurrent with the information release, the company also said that its venture funding has exceeded $100 million in total.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1